Consensus Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:30:03 16/01/2026 GMT			5-day change	1st Jan Change
31.01 ^USD	-3.24%		+13.10%	+12.41%

01-11	Beam Therapeutics sets strategic priorities for its genetic disease & hematology franchises	RE
01-07	UBS Initiates Beam Therapeutics at Neutral With $28 Price Target	MT

Evolution of the Average Target: Beam Therapeutics Inc.

Evolution of the Target Price: Beam Therapeutics Inc.

Changes in Analyst Recommendations: Beam Therapeutics Inc.

9d91e8cfda3e5eb.rp0YP97J07IpfYAElYnn6Wb8--NYrcTkquz5z1H_R2U.mud9S4qthON8OMRT3LCI2yW-z6UulZLQk9zOhQS9dh_mrUpZj76q1Ho60Q~b7bb6e10b46f8c3621bf4edef32870d5

Analysts' recommendations: Beam Therapeutics Inc.

01-07	UBS Initiates Beam Therapeutics at Neutral With $28 Price Target	MT
01-06	BofA Adjusts Price Target on Beam Therapeutics to $45 From $43, Maintains Buy Rating	MT
09/10/25	Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target	MT
03/04/25	RBC Cuts Price Target on Beam Therapeutics to $20 From $26, Keeps Sector Perform, Speculative Risk	MT
28/03/25	BofA Securities Upgrades Beam Therapeutics to Buy From Neutral	MT
10/03/25	Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target	MT
26/02/25	RBC Raises Price Target on Beam Therapeutics to $26 From $24, Keeps Sector Perform, Speculative Risk	MT
29/01/25	Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight From Neutral	MT
06/11/24	Beam Therapeutics Gets Upgrade From Leerink Partners; Shares Rise	MT
06/11/24	RBC Capital Adjusts Price Target on Beam Therapeutics to $24 From $27, Maintains Sector Perform, Speculative Risk Rating	MT
06/11/24	Leerink Partners Upgrades Beam Therapeutics to Outperform From Market Perform, Adjusts PT to $39 From $27	MT
16/10/24	Scotiabank Initiates Beam Therapeutics at Sector Perform With $24 Price Target	MT
18/09/24	JonesTrading Initiates Beam Therapeutics at Hold	MT
23/07/24	Beam Therapeutics Shares Rise After HC Wainwright Starts Coverage at Buy	MT
23/07/24	HC Wainwright Initiates Beam Therapeutics at Buy With $80 Price Target	MT
09/07/24	RBC Cuts Price Target on Beam Therapeutics to $27 From $35, Keeps Sector Perform, Speculative Risk	MT
28/06/24	Beam Therapeutics Insider Sold Shares Worth $1,470,156, According to a Recent SEC Filing	MT
04/04/24	Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	MT
28/02/24	Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	MT
28/02/24	RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	MT
27/02/24	Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating	MT
29/01/24	JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38	MT
15/12/23	BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35	MT
08/12/23	Jefferies Downgrades Beam Therapeutics to Hold From Buy, Cuts Price Target to $30 From $75	MT
17/10/23	Cantor Fitzgerald Lowers Price Target on Beam Therapeutics to $32 From $56, Maintains Overweight Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BEAM THERAPEUTICS INC.					+41.03%
	LONZA GROUP AG					+20.19%
	IQVIA HOLDINGS INC.					+7.61%
	BEONE MEDICINES AG					+19.67%
	CELLTRION, INC.					+12%
	REVOLUTION MEDICINES, INC.					-26.18%
	MEDPACE HOLDINGS, INC.					-11.7%
	EUROFINS SCIENTIFIC SE					-6.36%
	ICON PUBLIC LIMITED COMPANY					+12.67%
	Average					+7.66%
	Weighted average by Cap.					+7.77%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

32.05USD

Average target price

45.20USD

Spread / Average Target

+41.03%

High Price Target

80.00USD

Spread / Highest target

+149.61%

Low Price Target

21.00USD

Spread / Lowest Target

-34.48%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
BofA Securities
Jefferies & Co.
RBC Capital Markets
Scotiabank
Cantor Fitzgerald
Leerink Partners
JonesTrading Institutional Services
Barclays
Wedbush
JPMorgan Chase
Credit Suisse
Citigroup
Bernstein
Wells Fargo Securities
SVB Securities LLC
BMO Capital
Guggenheim
SVB Leerink
Redburn
J.P. Morgan Chase